Entrada Therapeutics’ $116 Million Series B Financing

White & Case LLP advised Qatar Investment Authority on the deal.

Qatar Investment Authority (QIA), the sovereign wealth fund of the State of Qatar, participated in a US$116 million Series B financing of Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics.

The financing closed on March 31, 2021.

The White & Case team which advised QIA on the transaction was led by partner Gary Silverman (Chicago; Picture) and included partners Andrew Kreisberg (Los Angeles) and Anita Varma (Boston), counsel Kenneth Barr (New York), and associates David Smith (Frankfurt), Matthew Sieben (Chicago), Ilan Har-El (New York), Ajita Shukla (Washington, DC), Yang Xu (Silicon Valley) and Anthony Veveakis (New York).

Involved fees earner: Kenneth Barr – White & Case; Ilan Har-El – White & Case; Andrew Kreisberg – White & Case; Ajita Shukla – White & Case; Matthew Sieben – White & Case; Gary Silverman – White & Case; David Smith – White & Case; Anita Varma – White & Case; Anthony Veveakis – White & Case; Yang Xu – White & Case;

Law Firms: White & Case;

Clients: Qatar Investment Authority;

Print Friendly, PDF & Email

Author: Martina Bellini